Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
A common blood pressure medication called hydralazine may cause ANCA-associated vasculitis (AAV), with a severe impact on both lungs and kidneys in rare instances, a case report shows. The ... Read more
To better understand the concerns and behaviors of people with autoimmune conditions during the COVID-19 pandemic, the Global Healthy Living Foundation (GHLF) and its digital patient community, CreakyJoints, have launched ... Read more
The multiple sclerosis treatment Lemtrada (alemtuzumab) can cause severe ANCA-associated vasculitis in rare cases, adding to the growing number of autoimmune complications caused by this therapy, a case report ... Read more
High doses of corticosteroids as initial treatment and kidney problems evident at diagnosis significantly increase the likelihood of early and severe infections in elderly people with ANCA-associated vasculitis (AAV), ... Read more
Among ANCA-associated vasculitis patients in remission — particularly those with manifestations in their kidneys — the reappearance of MPO-ANCA antibodies may be a sign of disease relapse, a study ... Read more
A combination of belimumab plus standard maintenance treatment is no better than standard of care alone at delaying relapse in ANCA-associated vasculitis (AAV) patients in remission, a Phase 3 clinical trial shows. ... Read more
The immunosuppressant agent mycophenolate mofetil (MMF) is similar to standard cyclophosphamide at inducing remission in ANCA-associated vasculitis (AAV) patients, but it seems to be associated with a higher relapse ... Read more
Disease status at three and six months seems to predict long-term survival and kidney failure in patients with ANCA-associated vasculitis (AAV), a study shows. These findings suggest that early disease ... Read more
The U.S. Food and Drug Administration has approved a label update for Rituxan (rituximab) to include information for patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) who ... Read more